D. Kirkpatrick
Vorstandsvorsitzender bei ENSYSCE BIOSCIENCES, INC.
Vermögen: 870 $ am 30.04.2024
Aktive Positionen von D. Kirkpatrick
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ENSYSCE BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 01.01.2009 | - |
Vorstandsvorsitzender | 01.01.2009 | - | |
Präsident | 01.01.2009 | - |
Karriereverlauf von D. Kirkpatrick
Ehemalige bekannte Positionen von D. Kirkpatrick
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2006 | 31.12.2008 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | Technik-/Wissenschafts-/F&E-Leiter | - | 11.12.2007 |
ProlX Pharmaceuticals Corp.
ProlX Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Seagen Inc., ProlX Pharmaceuticals Corp. is a biopharmaceutical company that manufactures biopharmaceutical products. The company is based in Tucson, AZ. The company was founded by D. Lynn Kirkpatrick. ProlX Pharmaceuticals was acquired by Biomira, Inc. on October 31, 2006 for $23.92 million. | Vorstandsvorsitzender | 01.01.1999 | 01.01.2006 |
Gründer | 01.01.1999 | 01.01.2006 | |
Präsident | 01.01.1999 | 01.01.2006 | |
University of Regina | Corporate Officer/Principal | 01.01.1983 | 01.01.2001 |
Phusis Therapeutics, Inc.
Phusis Therapeutics, Inc. BiotechnologyHealth Technology Phusis Therapeutics, Inc. is a private company that specializes in molecule therapeutics for cancer therapy. The company is based in Houston, TX and was founded by D. Lynn Kirkpatrick. The company focuses on developing inhibitors for PLEKHA7, RAL, Tiam1, and CERK, which are all important in cancer treatment. | Gründer | 01.01.2009 | - |
BiologicsMD, Inc.
BiologicsMD, Inc. Pharmaceuticals: MajorHealth Technology BiologicsMD, Inc. operates as early stage therapeutic development company. It focuses on developing highly-targeted or smart therapies for the treatment of hair loss diseases and conditions, as well as severe bone disorders. The company is headquartered in Fayetteville, AR. | Direktor/Vorstandsmitglied | - | - |
Ensysce Biosciences, Inc. /Old/
Ensysce Biosciences, Inc. /Old/ Medical DistributorsDistribution Services Ensysce Biosciences, Inc. supplies drugs for pain and cancer markets. Its technologies include opioid drug abuse-resistant, single-walled carbon nanotubes, SWCNT-immuno and gene therapy and BIO-MD prodrug technology. The company was founded by Bob G. Gower and William H.C. Chang in 2008 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.01.2009 | - |
Vorstandsvorsitzender | 01.01.2009 | - | |
Präsident | 01.01.2009 | - |
Ausbildung von D. Kirkpatrick
University of Saskatchewan | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Kanada | 4 |
Operativ
Chief Executive Officer | 3 |
President | 3 |
Director/Board Member | 3 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ENSYSCE BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | Health Services |
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
ProlX Pharmaceuticals Corp.
ProlX Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Seagen Inc., ProlX Pharmaceuticals Corp. is a biopharmaceutical company that manufactures biopharmaceutical products. The company is based in Tucson, AZ. The company was founded by D. Lynn Kirkpatrick. ProlX Pharmaceuticals was acquired by Biomira, Inc. on October 31, 2006 for $23.92 million. | Health Technology |
Ensysce Biosciences, Inc. /Old/
Ensysce Biosciences, Inc. /Old/ Medical DistributorsDistribution Services Ensysce Biosciences, Inc. supplies drugs for pain and cancer markets. Its technologies include opioid drug abuse-resistant, single-walled carbon nanotubes, SWCNT-immuno and gene therapy and BIO-MD prodrug technology. The company was founded by Bob G. Gower and William H.C. Chang in 2008 and is headquartered in San Diego, CA. | Distribution Services |
BiologicsMD, Inc.
BiologicsMD, Inc. Pharmaceuticals: MajorHealth Technology BiologicsMD, Inc. operates as early stage therapeutic development company. It focuses on developing highly-targeted or smart therapies for the treatment of hair loss diseases and conditions, as well as severe bone disorders. The company is headquartered in Fayetteville, AR. | Health Technology |
Phusis Therapeutics, Inc.
Phusis Therapeutics, Inc. BiotechnologyHealth Technology Phusis Therapeutics, Inc. is a private company that specializes in molecule therapeutics for cancer therapy. The company is based in Houston, TX and was founded by D. Lynn Kirkpatrick. The company focuses on developing inhibitors for PLEKHA7, RAL, Tiam1, and CERK, which are all important in cancer treatment. | Health Technology |
- Börse
- Insiders
- D. Kirkpatrick
- Erfahrung